Form 4: Vaxart Director James Breitmeyer Receives Equity Grant

Director James B. Breitmeyer acquired 78,800 shares and 157,400 stock options as part of a board compensation grant.

Summary

• Director James B. Breitmeyer was granted 78,800 shares of common stock.
• Director James B. Breitmeyer was granted 157,400 stock options with an exercise price of $0.7399.
• Both the restricted stock units and the stock options vest in equal installments over three years, contingent on continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the company's operational outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Long-term retention incentive created by the three-year vesting schedule.

Negatives

• Filing was submitted late due to administrative delays in receiving EDGAR access codes.

Risks

• Continued service requirement for vesting creates dependency on board stability.
• Potential dilution of existing shareholders through the issuance of new equity.

Future Outlook

The equity grants are subject to a three-year vesting schedule, implying the director is expected to remain on the board through at least April 2029 to fully vest the awards.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is standard practice in the biotechnology sector to align director incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a three-year vesting schedule for director equity is consistent with standard corporate governance practices for small-cap biotech firms.
• Granting a mix of restricted stock and options is a common compensation structure to balance ownership and performance-based incentives.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new shares.
• The board demonstrates commitment to the company through long-term equity holding.

Next Steps

• Vesting of the first installment of restricted stock units and options on 04/23/2027.

Key Dates

Keywords

Vaxart, VXRT, Form 4, Insider Trading, Director Compensation, Equity Grant